glp-1 for mash Exploring the Potential of Agonists in Incretin-based therapies in MASLD/MASH: from

That gets back to the preclinical and clinical obesity

3.5 Anti-diabetic drugs Anti-diabetic medications have been shown to improve outcomes in NAFLD/NASH and consequent liver fibrosis, even without an established diagnosis of diabetes mellitus

Concerns Regarding Fluid Retention and Arrhythmic Risk One important concern regarding the use of GLP-1RAs in patients with HFrEF is the risk of fluid retention, as highlighted in a study involving liraglutide

In the field of research and development of multi-target receptor agonist drugs, there are currently several multi-receptor agonists under research in the world that have entered the clinical stage